ASPI subsidiary Noble to merge into ENDRA Life Sciences with $50M investment; renamed Noble Africa Inc.

ASP Isotopes Inc.

Merger: Noble (ASPI subsidiary) merges into ENDRA; each Noble unit converts to one share of Class A or Class B common stock.
Noble Investment: ~$50M gross proceeds from 4.59M Class A units at $6.57/unit to institutional investors and 3.05M Class B units to ASPI.
ASPI contributes its Renergen subsidiary to Noble for 55.5M Class B units, entitling ASPI to 10 votes per share in ENDRA.
Closing conditions include ENDRA stockholder approval, SEC effectiveness, Nasdaq listing, OPIC consent, and ENDRA having ≥$3.8M cash.
Expected closing by Dec 24, 2026; ASPI directors (Mann, Ryan, Ainscow, Moore) subscribe for ~$750K of Noble Class A units.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.